4//SEC Filing
ONYX PHARMACEUTICALS INC 4
Accession 0001181431-13-052511
CIK 0001012140operating
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 9:01 PM ET
Size
22.7 KB
Accession
0001181431-13-052511
Insider Transaction Report
Form 4
LUNDBERG MAGNUS
Director
Transactions
- Disposition to Issuer
Stock Options
2013-10-01−2,000→ 0 totalExercise: $76.79From: 2013-07-25Exp: 2022-07-24→ Common Stock (2,000 underlying) - Disposition to Issuer
Stock Options
2013-10-01−10,000→ 0 totalExercise: $31.70From: 2008-06-08Exp: 2017-06-08→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Options
2013-10-01−4,041→ 0 totalExercise: $28.55From: 2010-03-31Exp: 2019-03-31→ Common Stock (4,041 underlying) - Disposition to Issuer
Common Stock
2013-10-01$125.00/sh−2,100$262,500→ 0 total - Disposition to Issuer
Stock Options
2013-10-01−10,000→ 0 totalExercise: $33.70From: 2009-06-09Exp: 2018-06-09→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Options
2013-10-01−5,000→ 0 totalExercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Options
2013-10-01−5,000→ 0 totalExercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (5,000 underlying) - Disposition from Tender
Common Stock
2013-10-01$125.00/sh−12,116$1,514,500→ 2,100 total - Disposition to Issuer
Stock Options
2013-10-01−5,000→ 0 totalExercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Options
2013-10-01−5,900→ 0 totalExercise: $88.86From: 2014-03-28Exp: 2023-03-27→ Common Stock (5,900 underlying)
Footnotes (2)
- [F1]These restricted stock awards were cancelled at the effective time of the merger (the "Merger") pursuant to the Agreement and Plan of Merger, dated August 24, 2013, by and among Onyx Pharmaceuticals, Inc. ("Onyx"), Amgen Inc. and Arena Acquisition Company (the "Merger Agreement") in exchange for an aggregate cash payment equal to the number of shares of Onyx's common stock underlying such restricted stock awards multiplied by the per share purchase price of $125.00.
- [F2]Represents options to purchase Onyx's common stock that were subject to vesting over time but were cancelled in the Merger in exchange for a cash payment in the amount by which the per share purchase price of $125.00 exceeded the exercise price of the option as of the effective time of the Merger.
Documents
Issuer
ONYX PHARMACEUTICALS INC
CIK 0001012140
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001012140
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 9:01 PM ET
- Size
- 22.7 KB